---
canonical_url: https://www.stockexpertai.com/earnings/ew
last_updated: 2026-05-05T21:53:41.416Z
---

# Edwards Lifesciences Corporation (EW) Q4 FY2026 Earnings Preview

> This content was automatically generated with FMP live data + Q4 FY2025 earnings call transcript. Generated: 2026-05-05T21:53:41.117Z. Educational tool, not investment advice.

---

## Quick Summary

| Field | Value | Source |
|---|---|---|
| Price | $82.91 (▼ -0.50%) | fmp:quote |
| Market Cap | $47.8B | fmp:profile |
| 52w range | $72.30 – $87.89 | fmp:quote |
| Earnings | Thu 23 Jul | fmp:earnings-history |
| EPS estimate | $0.74 (+10% YoY) | fmp:earnings-estimate |
| Revenue estimate | $1.7B | fmp:earnings-estimate |
| Beat streak | 1/4 | fmp:earnings-history |
| Rating | C- (overall 1/5) | fmp:ratings |
| Analyst median target | $95 (+14.6% upside) | fmp:price-target-consensus |
| MoonshotScore | 63/100 | derived |
| Council | 2/6 bullish | derived |
| Munger verdict | Fairly Valued | derived |

## Edwards Lifesciences Corporation — Q4 FY2026 Expectations

Q4 consensus: revenue <strong data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvgLabel">$1.7B</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.revenueAvg" title="FMP est">[FMP est]</sup>, EPS <strong data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">$0.74</strong><sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg" title="FMP est">[FMP est]</sup>. 1 consecutive quarters of beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.beatStreakCount" title="FMP earnings">[FMP earnings]</sup>.

## Quick Take

**Score:** C- · **Stance:** HOLD · **Council:** 2/6 · **Moonshot:** 63

= MoonshotScore <strong>63</strong><sup class="cite" data-source="derived" data-field="moonshot.score" title="9-pillar formula">[9-pillar formula]</sup> + Council <strong>2/6</strong><sup class="cite" data-source="derived" data-field="council.bullishCount" title="6-lens rule">[6-lens rule]</sup>. Form 4: 0 transactions<sup class="cite" data-source="fmp:insider-trading" data-field="insider.txCount" title="FMP Form 4">[FMP Form 4]</sup>.

## Watchlist (4 metrics)

### 1. 2026 EPS Guidance

Edwards Lifesciences indicates an earnings per share (EPS) guidance of $2.90 to $3.05 for 2026.

> "We have increased confidence in meeting our 2026 full-year sales growth rate guidance of 8% to 10%, and earnings per share guidance of $2.90 to $3.05."
> — Scott Ullem, CFO, Expectation / Guide · Q4 FY2025

### 2. TMTT Revenue Target

Edwards Lifesciences aims to achieve $2 billion in revenue from the TMTT segment in 2030.

> "Together, these are significant advancements for mitral and tricuspid patients and represent large opportunities to achieve our $2 billion revenue expectation for TMTT in 2030."
> — Bernard Zovighian, CEO, Investor Focus · Q4 FY2025

### 3. 2026 Sales Growth Guidance

Edwards Lifesciences maintains its sales growth guidance of 8% to 10% for 2026.

> "Overall, for Edwards Lifesciences Corporation in 2026, we have increased confidence in meeting our 8% to 10% sales growth guidance as well as EPS guidance."
> — Bernard Zovighian, CEO, Expectation / Guide · Q4 FY2025

### 4. Surgical Product Growth

Edwards Lifesciences expects mid-single-digit sales growth rate in Surgical products in 2026 driven by continued adoption of RESILIA therapies.

> "We continue to expect mid-single-digit sales growth rate in Surgical in 2026 driven by continued adoption of our RESILIA therapies that offer extended durability of our surgical therapies."
> — Bernard Zovighian, CEO, Investor Focus · Q4 FY2025


## MoonshotScore Pillars

| Pillar | Score | Level | Evidence |
|---|---|---|---|
| Revenue Growth | 4.0 | medium | Q1 vs Q2: moderate growth (+7.6%) |
| Gross Margin | 8.0 | strong | Q1: very high margin (78.2%, software/cloud territory) |
| Operating Leverage | 3.0 | weak | op margin very strong (31.2%, scale leverage) |
| Cash Runway | 10.0 | strong | FCF very strong ($0.4B, 3.6× CapEx) |
| R&D Intensity | 5.0 | medium | high R&D intensity (17.3%, aggressive) |
| Price Momentum | 7.0 | strong | RSI 53.9 balanced, 50d above |
| News Sentiment | 7.0 | strong | strong buy consensus (73%) |

**Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula.

## Council (7-Lens)

| Name | Stance | Context |
|---|---|---|
| Ray Dalio | bull | macro · target upside +14.6% |
| Ken Griffin | bull | flow · 50d MA above |
| Jim Simons | neutral | quant · RSI 54 |
| Klarman | neutral | value · target upside +14.6% |
| Buffett | neutral | quality · ROE score 1/5 |
| Munger | neutral | valuation · target upside +14.6% |

**Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr.

## Munger Lens

- **Verdict:** Fairly Valued
- **Financial Health:** Weak
- **Margin of Safety:** Moderate
- **Interest Coverage:** Adequate
- **ROIC vs WACC:** Tight

**Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget.

## Technical Levels

- **RSI(14):** 53.9 — dengeli — yön sinyali zayıf
- **50d MA:** $82 — hisse %0.8 üstünde — kısa vadeli destek
- **200d MA:** $81 — hisse %2.2 üstünde — uzun vadeli destek
- **Volume (10d):** -60%

## Past Performance (4 Quarters)

| Quarter | EPS Actual | EPS Estimate | Result | Reaction |
|---|---|---|---|---|
| Q2 FY25 | $0.67 | $0.62 | BEAT | +5.5% |
| Q3 FY25 | $0.67 | $0.60 | BEAT | -1.2% |
| Q4 FY25 | $0.58 | $0.62 | MISS | +3.0% |
| Q1 FY26 | $0.78 | $0.73 | +7.0% EPS | +5.6% |

Q4 (February 10, 2026): EPS $0.78 vs $0.73 est<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, +7.0% beat. D+1 movement: +5.6%<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP D+1">[FMP D+1]</sup>. Decline despite beat — market reacted to guidance, not numbers.

## 3 Scenarios

### Scenario A · Beat
**Q4 EPS > $0.74 + CapEx discipline**

Threshold: EPS > $0.74<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>.

Target: Break above median target $95<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP target]</sup>; high target $110<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.high">[FMP]</sup> upper bound.

### Scenario B · In-Line
**EPS ≈ $0.74 + CapEx < $97.4M**

Threshold: EPS ≈ $0.74<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est]</sup>, Q4 CapEx < $97.4M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel">[FMP]</sup>.

Target: Consolidation in the band between current $83<sup class="cite" data-source="fmp:quote" data-field="quote.price">[FMP]</sup> and median $95<sup class="cite" data-source="fmp:price-target-consensus" data-field="priceTarget.median">[FMP]</sup>.

### Scenario C · Miss
**EPS < $0.72 or CapEx ≥ $97.4M**

Threshold: EPS < $0.72<sup class="cite" data-source="fmp:earnings-estimate" data-field="estimates.next.epsAvg">[FMP est×0.97]</sup>.

Target: Current $83 below SMA200 $81<sup class="cite" data-source="fmp:technical" data-field="technical.sma200">[FMP]</sup>, if rejection continues, $69<sup class="cite" data-source="derived" data-field="technical.sma200" data-formula="round(sma200*0.85)">[derived]</sup> support activates.

## Risk Notes

### Primary segment below threshold
Q4: EPS $0.78 vs $0.73 beat<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.history.0" title="FMP">[FMP]</sup>, stock +5.6% D+1<sup class="cite" data-source="fmp:earnings-history" data-field="earnings.timeline.3.reactionLabel" title="FMP">[FMP]</sup>.

### Backlog concentration
No RPO/backlog concentration disclosed in Q4 earnings call.

### Insider trading
Form 4 data is marked in the table — this page does not generate assumptions for this stock.

| Executive | Action | Amount | Date |
|---|---|---|---|


**Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26

### CapEx shock
Q4 CapEx $97.4M<sup class="cite" data-source="fmp:cashflow" data-field="cashflow.qPrev.capexLabel" title="FMP cashflow">[FMP cashflow]</sup>. Q4 op margin 31.2%<sup class="cite" data-source="fmp:income" data-field="income.quarters.0.operatingMargin" title="FMP op margin">[FMP op margin]</sup> — this level in Q4 is sensitive to CapEx revision risk.

## Wall Street Consensus

- **Median target:** $95 (+14.6% upside vs current $83)
- **High / Low:** $110 / $85
- **Buy / Hold / Sell:** 22 / 8 / 0
- **Analyst count:** 9 (last quarter), 99 all-time

## Additional Transcript Insights

### 1. 2026_sales_growth_guidance

**Claim:** Edwards Lifesciences maintains its sales growth guidance of 8% to 10% for 2026.

**Evidence (transcript):** "Overall, for Edwards Lifesciences Corporation in 2026, we have increased confidence in meeting our 8% to 10% sales growth guidance as well as EPS guidance."

**Numbers:** 8%, 10%

### 2. TMTT_revenue_target

**Claim:** Edwards Lifesciences aims to achieve $2 billion in revenue from the TMTT segment in 2030.

**Evidence (transcript):** "Together, these are significant advancements for mitral and tricuspid patients and represent large opportunities to achieve our $2 billion revenue expectation for TMTT in 2030."

**Numbers:** $2, 2030

### 3. TAVR_market_growth

**Claim:** There is a rising clinical urgency for TAVR procedures due to the long-term durability and proven valve performance of the SAPIEN platform.

**Evidence (transcript):** "SAPIEN's growth globally was supported by rising clinical urgency for intentional proactive disease management. And long-term evidence demonstrating the proven durability and valve performance of SAPIEN."

**Numbers:** —

### 4. TMTT_growth_drivers

**Claim:** Global adoption of PASCAL and EVOQUE, along with the launch of SAPIEN M3 in the U.S. and Europe, expands Edwards Lifesciences' treatment portfolio for mitral and tricuspid patients.

**Evidence (transcript):** "With PASCAL and EVOQUE growing globally, and now with the introduction of SAPIEN M3 in the U.S. and Europe, Edwards Lifesciences Corporation continues to deliver on our vision of offering a portfolio of therapies to treat more mitral and tricuspid patients."

**Numbers:** —

### 5. surgical_product_growth

**Claim:** Edwards Lifesciences expects mid-single-digit sales growth rate in Surgical products in 2026 driven by continued adoption of RESILIA therapies.

**Evidence (transcript):** "We continue to expect mid-single-digit sales growth rate in Surgical in 2026 driven by continued adoption of our RESILIA therapies that offer extended durability of our surgical therapies."

**Numbers:** 2026

### 6. 2026_EPS_guidance

**Claim:** Edwards Lifesciences indicates an earnings per share (EPS) guidance of $2.90 to $3.05 for 2026.

**Evidence (transcript):** "We have increased confidence in meeting our 2026 full-year sales growth rate guidance of 8% to 10%, and earnings per share guidance of $2.90 to $3.05."

**Numbers:** 2.90, 3.05, 2026, 8%, 10%


---

*Data source: FMP (live query, 2026-05-05), Q4 FY2025 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*